INmune BioINMB +1.19%57 Net Debt Paydown Yield % is 2.77% as of Jul. 04, 2026, which is 9133% above its 10-year median of 0.03. GuruFocus rates INMB with a GF Score™ of 57/100 and a GF Value™ of $1.82 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,163 Biotechnology companies, INmune Bio ranks better than 83.32% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, INmune Bio's Net Debt Paydown Yield % was 2.77%.
INmune Bio (NAS:INMB) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
INmune Bio Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for INmune Bio's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INMB vs GRCE, NTRB, ABVC: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, INmune Bio's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
INmune Bio Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, INmune Bio's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where INmune Bio's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 2.77% mean?
INmune Bio (INMB) has a Net Debt Paydown Yield % of 2.77% as of Jul. 04, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on INmune Bio and its competitors. This is 9133% above median its historical median of 0.03. According to the industry distribution chart, INmune Bio ranks #194 out of 1163 companies in the Biotechnology industry, placing it in the top 16.7%.
Is INmune Bio's Net Debt Paydown Yield % too high?
INmune Bio's current Net Debt Paydown Yield % of 2.77% is 9133% above median its 10-year median of 0.03. The Biotechnology industry median Net Debt Paydown Yield % is 0.03. INmune Bio's value of 2.77% is 9133.3% above this industry median. Based on the distribution chart, INmune Bio ranks #194 out of 1163 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, INmune Bio has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does INmune Bio's Net Debt Paydown Yield % compare to GRCE and NTRB?
According to the Biotechnology industry distribution chart, INmune Bio ranks #194 out of 1163 companies for Net Debt Paydown Yield %. This places INmune Bio in the top 17% of its industry — outperforming the majority of peers. The industry median Net Debt Paydown Yield % is 0.03. INmune Bio's value of 2.77% is 9133.3% above this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 0.03, INmune Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,163 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. INmune Bio's current Net Debt Paydown Yield % of 2.77% is 9133.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on INmune Bio and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. INmune Bio's current Net Debt Paydown Yield % is 2.77%, which is 9133% above median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INmune Bio stock overvalued right now?
Based on GuruFocus' analysis, INmune Bio (INMB) is currently considered Fairly Valued. The stock's GF Value™ is $1.82, compared to a current price of $1.70 — trading 6.6% below its estimated fair value. The current Net Debt Paydown Yield % is 2.77%, which is 9133% above median its 10-year median of 0.03 and 9133.3% above the Biotechnology industry median of 0.03. INmune Bio's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For INmune Bio (INMB), the current Net Debt Paydown Yield % is 2.77% as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is INmune Bio (INMB) Overvalued in 2026?
Based on GuruFocus' analysis, INmune Bio stock appears to be undervalued.
The current stock price of $1.70 is trading 6.6% below its estimated GF Value™ of $1.82.
GuruFocus considers INmune Bio to be Fairly Valued.
Key valuation signals for INMB:
Net Debt Paydown Yield %: 2.77% (9133% above median its 10-year median of 0.03)
GF Value™: $1.82 vs. price of $1.70 (6.6% below fair value)
Industry Position: 9133.3% above the Biotechnology median (#194 of 1163)
No single metric tells the full story. See the INMB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
57GF Score
Get the complete analysis for INMB
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INMB has been successfully added to your 
